CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Inclusion Criteria:

• Adult patients 18 years of age or older with:

• newly diagnosed early-staged localized pancreatic ductal adenocarcinoma (PDAC)scheduled to undergo Whipple procedure (cohort 1a) or down-staged afterneoadjuvant chemotherapy now eligible to undergo resection OR

• borderline resectable, locally advanced, metastatic, or recurrent PDAC (cohort 1b) scheduled to undergo chemotherapy OR

• borderline resectable, locally advanced PDAC (cohort 2) who is eligible and /or signed consent to undergo CCR2-targeted therapy example:[(phase 1/2 clinicaltrial combining an oral CCR2/5i (BMS-813160) with chemotherapy (gemcitabineplus nab-paclitaxel) and anti-PD-1 (nivolumab), PI, Dr. Kian Lim) HRPO

#201806007 - closed to accrual March 2022] AND

• at least one measurable [defined as lesions that can be accurately measured inat least one dimension (longest diameter to be recorded) as ≥ 10 mm with CTscan or MRI] A cohort 1B subject who has been previously treated for PDAC witha diagnosis of recurrence and a lesion size of 1.5 cm or greater will beallowed to enroll before institution of therapy or within 20 days afterstarting a 2nd line or later (new therapy) for recurrent disease.

• Able to give informed consent

• Not currently pregnant or nursing: Subject must be surgically sterile (has had adocumented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearingpotential for whom a urine pregnancy test (with the test performed within the 24hour period immediately prior to administration of 64Cu-DOTA-ECL1i) is negative

Exclusion Criteria:

• Patients with other invasive malignancies, with the exception of non-melanoma skincancer, who had (or have) any evidence of the other cancer present within the last 5years

• Unable to tolerate up to 90 min of PET/CT imaging per imaging session.